They are absolutely frightened by the prospect of a competitor coming in with a cheaper, more consistent and more potent product. Which is exactly what Cynata offers. If I held MSB and objectively read the announcement today, I would be petrified and running for the hills. That announcement conveys a management team that knows they are living on borrowed time.
What they specifically included and excluded from that announcement painted a clear picture of where they see the threat to their business model. That threat is Cynata.
Why Orphan Drug Designation for mesoblast is IRRELEVANT to Cynata, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
-0.005(2.78%) |
Mkt cap ! $39.54M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 17.5¢ | 17.5¢ | $6.287K | 35.92K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 67866 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 27766 | 2 |
View Market Depth
| Last trade - 11.42am 29/07/2025 (20 minute delay) ? |
| CYP (ASX) Chart |